Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
167.64
+5.56 (3.43%)
Nov 21, 2025, 4:00 PM EST - Market closed
CRL Stock Forecast
Stock Price Forecast
The 13 analysts that cover CRL stock have a consensus rating of "Buy" and an average price target of $190.15, which forecasts a 13.43% increase in the stock price over the next year. The lowest target is $165 and the highest is $210.
Price Target: $190.15 (+13.43%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CRL stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 4 | 4 | 4 |
| Buy | 0 | 1 | 1 | 1 | 3 | 4 |
| Hold | 13 | 10 | 10 | 10 | 9 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 14 | 14 | 15 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $170 → $185 | Hold | Maintains | $170 → $185 | +10.36% | Nov 11, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $205 → $197 | Strong Buy | Maintains | $205 → $197 | +17.51% | Nov 10, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $160 → $165 | Hold | Maintains | $160 → $165 | -1.57% | Nov 6, 2025 |
| Barclays | Barclays | Buy Maintains $195 → $210 | Buy | Maintains | $195 → $210 | +25.27% | Nov 6, 2025 |
| Baird | Baird | Hold → Buy Upgrades $178 → $199 | Hold → Buy | Upgrades | $178 → $199 | +18.71% | Nov 6, 2025 |
Financial Forecast
Revenue This Year
4.03B
from 4.05B
Decreased by -0.47%
Revenue Next Year
4.13B
from 4.03B
Increased by 2.43%
EPS This Year
10.29
from 0.20
Increased by 5,044.17%
EPS Next Year
10.88
from 10.29
Increased by 5.71%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.3B | 4.4B | |||
| Avg | 4.0B | 4.1B | |||
| Low | 3.9B | 3.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5.0% | 8.6% | |||
| Avg | -0.5% | 2.4% | |||
| Low | -4.6% | -2.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.01 | 12.31 | |||
| Avg | 10.29 | 10.88 | |||
| Low | 9.80 | 9.26 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 5,403.1% | 19.6% | |||
| Avg | 5,044.2% | 5.7% | |||
| Low | 4,800.0% | -10.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.